middle.news

Avecho Accelerates Phase III CBD Trial with New Sites and Manufacturing Milestone

6:44pm on Sunday 1st of June, 2025 AEST Biotechnology
Read Story

Avecho Accelerates Phase III CBD Trial with New Sites and Manufacturing Milestone

6:44pm on Sunday 1st of June, 2025 AEST
Key Points
  • Phase III trial dosing underway with 70 participants enrolled
  • Inclusion criteria broadened and two new trial sites added to accelerate recruitment
  • Interim analysis expected in 2025, a pivotal milestone for Avecho
  • Completed 11 tonnes of Vital-ET manufacturing for Ashland in 2024
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE